|1.||Wallis, Robert S: 3 articles (01/2012 - 09/2010)|
|2.||Campbell, Sheldon: 3 articles (01/2012 - 09/2010)|
|3.||Ladutko, Lynn: 3 articles (01/2012 - 09/2010)|
|4.||Mitton-Fry, Mark: 3 articles (01/2012 - 09/2010)|
|5.||Miller, Paul F: 3 articles (01/2012 - 09/2010)|
|6.||Paige, Darcy: 3 articles (01/2012 - 09/2010)|
|7.||Silvia, Annette: 2 articles (01/2012 - 02/2011)|
|8.||Jakubiec, Wesley: 2 articles (01/2012 - 02/2011)|
|9.||Zhu, Tong: 2 articles (02/2011 - 08/2009)|
|10.||Kumar, Vikas: 2 articles (02/2011 - 09/2010)|
02/01/2011 - "Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis."
08/15/2009 - "Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis."
04/01/2009 - "Another oxazolidinone, PNU-100480, has been demonstrated to have more potent activity in vitro and in a murine model of tuberculosis. "
09/01/2010 - "The oxazolidinone PNU-100480 is superior to linezolid against experimental murine tuberculosis. "
08/15/2009 - "We recently reported strong bactericidal activity of the oxazolidinone PNU-100480 and its ability to increase the initial bactericidal effect of various combinations of first-line tuberculosis drugs and moxifloxacin in a murine model. "
06/01/2014 - "Moreover, the potency of PNU-100480 was significantly greater than that of linezolid, making it an attractive drug candidate in the development of new combination therapies for latent tuberculosis. "
06/01/2014 - "Here, we compared the activities of three oxazolidinones, linezolid, PNU-100480, and AZD5847, against latent tuberculosis using a simple model employing the streptomycin-starved Mycobacterium tuberculosis strain 18b. "
|3.||Body Weight (Weight, Body)
05/01/1999 - "A dose-response study was performed with PNU-100480 and linezolid (both at 25, 50, and 100 mg/kg of body weight). "
04/01/2009 - "For example, the addition of PNU-100480 (100 mg/kg of body weight/day) to the standard daily regimen of rifampin (rifampicin), isoniazid, and pyrazinamide resulted in an additional 2.0-log(10)-unit reduction in lung CFU counts during the first 2 months of treatment. "
|4.||Extensively Drug-Resistant Tuberculosis
03/01/2011 - "Therefore, PNU-100480 is a promising candidate to be developed further as an adjunct in the treatment of multidrug- and extensively drug-resistant tuberculosis (MDR/XDR-TB)."
01/01/2012 - "Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide."
|5.||Multidrug-Resistant Tuberculosis (Drug-Resistant Tuberculosis)
08/15/2009 - "Together with previous findings, these results confirm that PNU-100480, which is now in Phase I clinical testing, has sterilizing activity in the murine model and suggest that it may be capable of shortening treatment duration for drug-susceptible as well as drug-resistant tuberculosis in humans."
04/01/2009 - "These results suggest that PNU-100480 may have the potential to significantly shorten the duration of therapy for drug-susceptible as well as multidrug-resistant tuberculosis."
|3.||1- (6- bromo- 2- methoxy- quinolin- 3- yl)- 4- dimethylamino- 2- (3- fluorophenyl)- 1- phenyl- butan- 2- ol (R207910)
|5.||Oxazolidinones (2 Oxazolidone)
|6.||Streptomycin (Streptomycin Sulfate)